Dashenlin Pharm Grp Co Ltd (603233) — Capital Reinvestment Ratio
Dashenlin Pharm Grp Co Ltd (603233) has a Capital Reinvestment Ratio of 0.20x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥818.72 Million) in capital expenditures (CN¥161.42 Million). See 603233 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Dashenlin Pharm Grp Co Ltd Capital Reinvestment Ratio (2012–2025)
This chart tracks Dashenlin Pharm Grp Co Ltd's Capital Reinvestment Ratio across 14 annual periods.
Annual Capital Reinvestment Ratio for Dashenlin Pharm Grp Co Ltd (2012–2025)
Year-by-year Capital Reinvestment Ratio for Dashenlin Pharm Grp Co Ltd from 2012 to 2025. For live market cap and broader valuation context, see Dashenlin Pharm Grp Co Ltd (603233) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | CN¥5.35 Billion | CN¥484.84 Million | ▼ -80.9% |
| 2024 | 0.48x | CN¥3.11 Billion | CN¥1.48 Billion | ▼ -16.1% |
| 2023 | 0.57x | CN¥3.17 Billion | CN¥1.80 Billion | ▲ +105.5% |
| 2022 | 0.28x | CN¥3.76 Billion | CN¥1.03 Billion | ▼ -66.9% |
| 2021 | 0.83x | CN¥1.55 Billion | CN¥1.29 Billion | ▲ +105.4% |
| 2020 | 0.41x | CN¥1.95 Billion | CN¥792.32 Million | ▲ +38.1% |
| 2019 | 0.29x | CN¥1.71 Billion | CN¥501.41 Million | ▼ -53.7% |
| 2018 | 0.63x | CN¥873.64 Million | CN¥554.39 Million | ▼ -39.2% |
| 2017 | 1.04x | CN¥640.39 Million | CN¥668.53 Million | ▲ +68.3% |
| 2016 | 0.62x | CN¥495.60 Million | CN¥307.35 Million | ▲ +17.3% |
| 2015 | 0.53x | CN¥468.59 Million | CN¥247.84 Million | ▼ -9.4% |
| 2014 | 0.58x | CN¥448.58 Million | CN¥261.82 Million | ▼ -53.8% |
| 2013 | 1.26x | CN¥288.22 Million | CN¥363.99 Million | ▲ +510.4% |
| 2012 | 0.21x | CN¥289.31 Million | CN¥59.85 Million | — |